GlucoVest™: Bonerge Launches Premium Dihydroberberine Ingredient for Metabolic Health Supplements
2024年7月11日 - 4:12PM
ビジネスワイヤ(英語)
Bonerge Lifesience is excited to announce the launch of its new
branded ingredient, GlucoVest, designed to support blood sugar and
lipid metabolism as well as weight management. As Berberine and its
so-called "natural Ozempic" gain viral popularity on TikTok, many
supplement brands incorporate Berberine into their products. To
meet the increasing demand for higher quality products, Bonerge
introduces GlucoVest, a superior Dihydroberberine ingredient,
offering a new option for supplement brands.
Dihydroberberine, GlucoVest’s active component, is a Berberine
derivative with similar benefits. Importantly, Dihydroberberine has
better bioavailability than Berberine. Unlike Berberine, which has
been reported to cause side effects such as vomiting,
Dihydroberberine has no report of adverse effects in published
toxicology studies.
Berberine's surge in popularity is due to its weight loss
mechanism similar to Semaglutide's. As both of them can boost the
secretion of GLP-1.1 GLP-1 increases satiety, reduces food intake,
enhances energy expenditure, and delays gastric emptying time.2
Besides its weight loss effects, research indicates that Berberine
can improve insulin sensitivity3, reduce blood sugar levels4, and
enhance lipid metabolism by promoting the conversion of white fat
to brown fat and lowering plasma LDL cholesterol, free fatty acids,
and total cholesterol levels. 4-5
Through extensive research and development, GlucoVest is
produced with a unique manufacturing procedure that yields
high-quality crystalline Dihydroberberine. Even the granulated
specifications, can maintain a high assay level compared to other
Dihydroberberine on the market while maintaining the flowability of
powder. This allows for maximizing the efficacy of Dihydroberberine
and providing brands with more versatile product applications.
To further explore the potential and possible applications of
GlucoVest, Bonerge plans to conduct self-GRAS certification,
efficacy studies, and human trials. For more information, please
contact Bonerge.
Reference
- Araj-Khodaei, Mostafa et al. “Berberine-induced glucagon-like
peptide-1 and its mechanism for controlling type 2 diabetes
mellitus: a comprehensive pathway review.”
- Baggio, Laurie L, and Daniel J Drucker. “Biology of incretins:
GLP-1 and GIP.”
- Kong, Wei-Jia et al. “Berberine reduces insulin resistance
through protein kinase C-dependent up-regulation of insulin
receptor expression.”
- Mi, Jia et al. “Effect of berberine on the HPA-axis pathway and
skeletal muscle GLUT4 in type 2 diabetes mellitus rats.”
- Hu, Xiaofei et al. “Berberine is a potential therapeutic agent
for metabolic syndrome via brown adipose tissue activation and
metabolism regulation.”
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240704974135/en/
Lily Liu Email: sales@bonerge.com